2-Amino-4-fluoropyridine | CAS:944401-77-8

We serve 2-Amino-4-fluoropyridine CAS:944401-77-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Amino-4-fluoropyridine

Chemical Name:  2-Amino-4-fluoropyridine
CAS.NO:944401-77-8
Synonyms:4-fluoropyridin-2-amine
4-Fluoro-2-pyridinamine
Molecular Formula:C5H5FN2
Molecular Weight:112.10500
 
Physical and Chemical Properties:
Density:1.3±0.1 g/cm3
Melting point:/
Boiling point:211.5±20.0 °C at 760 mmHg
Flash point:81.7±21.8 °C
Index of Refraction:1.554
 
Specification:
Appearance:White Crystalline Powder
Purity:≥98.0%
 
Packing:25 KGS/Drum
Storage:Refrigerated.Store in a tightly closed container. Store in a cool, dry
Application:  used in the pharmaceutical intermediate



Contact us for information like 2-Amino-4-fluoropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluoro-2-pyridinamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Amino-4-fluoropyridine Use and application,4-fluoropyridin-2-amine technical grade,usp/ep/jp grade.


Related News: ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses.methyl 3,3-dimethylacrylate manufacturer Vietnam recently barred almost all flights to and from mainland China, Hong Kong and Macau until May 1, according to the United States Federal Aviation Administration.1-((4-Fluorophenyl)carbamoyl)cyclopropanecarboxylic acid supplier The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.Glycidyl methacrylate vendor British Airways, Qantas and Lufthansa — among others — have announced they will stop flying to mainland China. Other airlines are reducing the number of flights.The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.